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Abstract
Background Sarcopenia in older adults is strongly associated with an increase in dependency in activities of daily living (ADL)
and with a decline in gait speed. Interestingly, gait speed has been shown to independently predict mortality. In this context,
our study aimed to explore the mediator role of gait speed on the relationship between sarcopenia and dependency in ADL.
Methods A cross-sectional study was conducted in Colombia, 19 705 older adults with a mean age of 70 years, 55.6%
women, 16.1% with sarcopenia, and 14.7% mild, moderate, or severe dependency in ADL, according to ‘SABE Survey 2015’.
Sarcopenia was assessed by calf circumference and ADL dependence through the Barthel Index. Gait speed was measured over
a distance of 3 m. The association between sarcopenia condition and gait speed and dependency level was analysed by linear
regression adjusted by covariates. To examine whether gait speed mediated the association between sarcopenia and depen-
dence components of physical function, simple mediation models were generated using ordinary least squares with the macro
PROCESS version 3.2, adjusted for age, sex, and body mass index (BMI).
Results Signiﬁcant differences (P< 0.05) were found in gait speed and dependency in ADL between the sarcopenia and non-
sarcopenia groups after adjusting for age, sex, and BMI. BMI was signiﬁcantly higher in the non-sarcopenia group whereas de-
pendency was signiﬁcantly higher in the sarcopenia group (19.6% vs. 13.8%). Results from mediation model regression analysis
indicated a signiﬁcant and direct detrimental effect of sarcopenia on dependency in ADL (β = 0.05; P < 0.001), and a signif-
icant indirect effect of gait speed on the direct effect (0.009 to 0.004).
Conclusions The negative effect of sarcopenia on functional dependence was mediated by the gait speed. Therefore, gait
speed may positively inﬂuence the detrimental effect of sarcopenia for dependency, after adjusting for age, gender, and
BMI. Consequently, physical exercise should be promoted and focused to circumvent the gait speed decline associated with
age in older people with sarcopenia.
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Introduction
Sarcopenia is an age-related loss of muscle mass and function
in older adults and may favour the appearance of cardiovas-
cular complications or neurodegenerative disorders1,2. While
its prevalence is variable depending on its localization and the
method of evaluation, it is estimated that 29% of older per-
sons in community-dwelling populations and 14–33% in
long-term care populations are affected by sarcopenia.3 In
Colombia, recent results from SABE Bogota study estimated
that sarcopenia affects 11.5% of the older population.4
Sarcopenia is related to several functional comorbidities
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including mobility disorders, risk of falls and fractures, and a
loss of physical independence in activities of daily living
(ADL).5,6 It seems that sarcopenia depends on several
coadjuvant factors such as inﬂammatory processes related
to aging, nutritional status, intramuscular fat, and genetics,
in addition to the reduction of physical activity, which is a cru-
cial precursor of sarcopenia.2,7 In the context of the afore-
mentioned factors, there is evidence to indicate that both
aerobic and resistance training promote a healthy anti-
inﬂammatory milieu largely through the release of muscle-
derived myokines,8 mitigate mitochondria-related dysfunc-
tion,8 and ameliorates age-related loss of muscle mass and
strength9 as well as functional capacity and physical
performance.10
As a locomotor capacity, gait speed is representative of
neuromuscular quality (morphological and neuronal)1 and a
critical determining factor for healthy aging. Indeed, the Eu-
ropean Working Group on Sarcopenia in Older People has de-
veloped an algorithm including gait speed measurement as
the easiest and most reliable way to determine sarcopenia
in clinical practice,11 and also this has been used to diagnose
functional disability and dependence in older adults.11–13 Cor-
respondingly, the loss of muscle mass and consequently the
declining of gait speed are age associated; for example, in a
4-year follow-up of older Chinese, the percentage decline in
gait speed was 8.2% and 9.0% in men and women,
respectively.14
On the other hand, sarcopenia, resulting from reduced
skeletal muscle mass, is associated with aging.15 Based on
the need for a simpler method of assessing muscle mass in
community-based, and large-scale epidemiological contexts,
several regions (Europe, USA, and Asia) and organizations in-
corporated the use of calf circumference (CC), as a marker of
muscle mass in elderly people in primary care setting11,16–18.
In a Japanese study including 526 participants, CC was
positively correlated with appendicular skeletal muscle and
as a surrogate marker of muscle mass for diagnosing
sarcopenia.19
In addition, the sarcopenia and the impairment of gait
speed are strongly associated to loss of independence in
ADL.20–22 Therefore, these have three factors related to
sarcopenia → declining of gait speed→ loss of independency
in ADL; and between them, a vicious circle is formed. Conse-
quently and taking into account the previous studies, 23,24 the
gait speed seems to be the key factor that can worsen this vi-
cious circle or on the contrary improve it. This possible role of
gait speed is known as a mediator role and can be explore
through mediation analysis. Statistical mediation analysis al-
lows us to understand how an independent variable ‘X’ af-
fects a dependent variable ‘Y’ through the indirect effect of
the mediating variable ‘M’.15 For instance, mediation analysis
could identify if gait speed do and do not mediate these ad-
verse effects of sarcopenia on dependency. This knowledge
could help to adjust physical activity program in older adults,
emphasizing the improvement of gait speed. Accordingly, the
mediator variable ‘M’ (gait speed) may play a role as the me-
diator of the relationship between the antecedent variable ‘X’
(sarcopenia) and the outcome variable ‘Y’ (loss of indepen-
dence)25 (Figure 1).
While it is known that the level of physical ﬁtness affects
independence and that exercise can counteract the detri-
mental effects of sarcopenia, to our knowledge, no studies
have addressed the role of the gait speed in the relationship
between sarcopenia and loss of functional independence.
Here, we hypothesized that gait speed could have an attenu-
ating effect on the relationship between sarcopenia and loss
of independence.
Method
Study design and sample population
The present study is part of the 2015 SABE study survey on
health, well-being, and aging in Latin America and the Carib-
bean. SABE is a multicentre project originally conducted by
the Pan-American Health Organization and supported by
the Epidemiological Ofﬁce of the National Health Ministry in
Bogotá, Colombia (https://www.minsalud.gov.co/). Details
of the survey have been published elsewhere.26
In brief, data collection took place between April and Sep-
tember 2015, and the response proportion ranged from
~62% in urban areas to 77% in rural sites.26 The estimated
sample size was 24 553 individuals, and assuming an 80% re-
sponse the target sample was 30 691 individuals.26 The esti-
mated sample size was 24 553 individuals, and assuming an
80% response the target sample was 30 691 individuals. How-
ever, at ﬁeldwork after implementing several strategies to
achieve the overall sample and prevent nonparticipation, re-
sponse proportion was about 70% and varied by region and
urban/rural distributions. The ﬁnal sample size achieved, in-
cluding 244 municipalities (n = 23 694 older adults) across
Figure 1 Statistical mediation simple diagram.
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all departments (i.e. states) of the country. Of the 23 694 par-
ticipants who took part in SABE Survey, a total of 19 705
remained in the present analysis after excluding participants
without a BMI (n = 1684), ADL (n = 1281), and CC
(n = 1024) values.
Institutional review boards at the two universities involved
in developing the SABE Colombia study [University of Caldas
(ID protocol CBCS-021-14) and University of Valle (ID protocol
09-014 and O11-015)] reviewed and approved the study pro-
tocol, and written informed consent was obtained from each
individual before inclusion and completion of the ﬁrst exami-
nation (including permission to use secondary data and blood
samples). Permission was obtained from the National Health
Ministry in Bogotá, Colombia, to use the publicly available
data for research and teaching purposes (Pontiﬁcia
Universidad Javeriana). The study protocol to the secondary
analysis was approved by the Human Subjects Committee at
the Pontiﬁcia Universidad Javeriana (ID 20/2017-2017/180,
FM-CIE-0459-17). Further details can be obtained from the





Body measurement assessments were collected by investiga-
tors trained in standardized measurement methods, previ-
ously trained by research staff from the coordinating
centres (Universities of Caldas and Valle). All information col-
lected were obtained through face-to-face interviews con-
ducted at each site on mobile capture devices (tablets) or
with printed versions of the questionnaire.
Body mass was measured using weighing scales to the
nearest 0.1 kg; height was measured using a stadiometer to
the nearest 0.1 cm, with the body mass index (BMI, kg/m2)
was subsequently derived. We deﬁned sarcopenia according
to CC, as proposed by Rolland et al.,27 as a ‘proxy’ measure
for assessing muscle mass and early identiﬁcation of
sarcopenia in clinical practice, due to the low cost and ease
of application. As described,27 a CC <31 cm is considered to
be indicative of low muscle mass. This cut-off has been rec-
ommended for use in older individuals by the WHO Expert
Committee.28 Thus, CC measures are practical have accept-
able accuracy for estimating sarcopenia when compared with
dual-energy X-ray absorptiometry, the gold standard for body
composition assessment.27 CC was measured at a plane per-
pendicular to the long axis of the calf while the participant
was sitting on chair or standing with foot ﬂat on the ﬂoor
using an inelastic tape measure. Thus, the CC values pre-
sented here combine the results of left-foot and right-foot
subjects, without consideration for lower body dominance.
Gait speed over a distance of 3 m was measured three times,
and the analysis used the shortest time of the three
attempts.
Functional impairment was assessed with an ADL evalua-
tion using a Spanish-adapted version of the physical level
ADL (Barthel Index).29 The items are weighted: a maximum
score of 100 indicates independence, 91–99 minimal depen-
dence, 75–90 mild dependence, 50–74 moderate depen-
dence, 25–49 severe dependence, and 0–24 total
dependence.30 The socio-economic level (I to VI), ethnic group
(indigenous, black ‘mulato’ or Afro-Colombian, white, and
others, mestizo, gitano, etc.), and tobacco smoking (patients
were categorized as those who do not smoke, those who have
never smoked, those who currently smoke, or those who pre-
viously smoked) were recorded. A ‘proxy physical activity’ was
evaluated by the following questions: (i) ‘Have you regularly
exercised, such as jogging or dancing, or performed rigorous
physical activity at least three times a week for the past year?’
(ii) ‘Do you walk at least three times a week between 9 and 20
blocks (1.6 km) without resting?’ And (iii) ‘Do you walk at least
three times a week 8 blocks (0.5 km) without resting?’ Those
participants who responded afﬁrmatively to two of the three
questions were considered physically active. Finally, nutri-
tional status was assessed by using the longer, original version
of the Mini-Nutritional Assessment and mobility disability was
deﬁned as having difﬁculty in walking 400m or climbing a
ﬂight of stairs without resting.26
Statistical analysis
Before statistical analysis was performed, the normality of var-
iables was tested using the Kolmogorov–Smirnov test. The
variables that presented non-uniformity were transformed
via natural logarithm or reciprocal transformation (1/x)
depending on positive or negative skew.31 For the descriptive
analysis of the sample, we used percentages and frequency
distributions for categorical variables, and mean with standard
deviation for continuous quantitative variables. The character-
istics of the participants with and without sarcopenia were
compared with the chi-squared test for categorical variables
and Student’s t-test for continues variables. The association
between sarcopenia condition and gait speed and depen-
dency level was analysed by linear regression using three
separate models. We entered sarcopenia as predictor variable
and gait speed and dependency categories as outcome vari-
ables and three separate models: Model 1 adjusted by sex,
gender, and BMI; Model 2 adjusted by Model 1 + nutritional
status; Model 3 adjusted by Model 2 and mobility disability.
To examine whether gait speed mediated the association
between sarcopenia and dependence components of physical
function, simple mediation models were generated using or-
dinary least squares with the macro PROCESS version 3.2, ad-
justed for age, sex, and BMI. Mediation hypotheses were
tested using the bias-corrected bootstrap method with 5000
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samples to calculate conﬁdence intervals (95%). An indirect
effect was considered signiﬁcant when the conﬁdence inter-
val did not include zero.25
Results
The descriptive characteristics and differences between the
sarcopenia and non-sarcopenia groups are shown in Table 1
. The classiﬁcation of sarcopenia according to the CC criterion
categorized 16.1% of older adults with sarcopenia, with a
higher prevalence of sarcopenia in women than in men. Re-
garding sociodemographic covariates, the results indicated a
higher prevalence of sarcopenia with advanced age and with
low socio-economic level. In total, 80.7% of the participants
with sarcopenia did not achieve the minimum level of recom-
mended physical activity proxy. Finally, BMI was signiﬁcantly
higher in the non-sarcopenia group whereas dependency
was signiﬁcantly higher in the sarcopenia group (19.6% vs.
13.8%).
Table 2 shows the associations between sarcopenia and
gait speed and dependency level. The results from regression
analysis indicate a signiﬁcant association between sarcopenia
and gait speed independently of age, gender, BMI, nutritional
status, and mobility disability. Likewise, the association be-
tween sarcopenia and dependency level is signiﬁcant when
adjusted the regression by age, gender, BMI, and nutritional
status; however, this association is not signiﬁcant when in-
cluded in the model the mobility disability.
Table 1 Sample characteristics stratiﬁed by sarcopenia status
Sample characteristics Sarcopenia (N = 3168) Non-sarcopenia (N = 16 537) Total (N = 19 705) P-value
Female, n (%) 2021 (18.4) 8943 (81.6) 10 964 (55.6) <0.001
Male, n (%) 1147 (13.1) 7594 (86.9) 8741 (44.4)
Age group, n (%)
60–64 621 (10.3) 5393 (89.7) 6014 (30.5) <0.001
65–69 640 (12.8) 4360 (87.2) 5000 (25.4)
70–74 644 (17.3) 3076 (82.7) 3720 (18.9)
75–79 585 (21.7) 2107 (78.3) 2692 (13.7)
80–84 392 (26.5) 1086 (73.5) 1478 (7.5)
85+ 286 (35.7) 515 (64.3) 801 (4.1)
Socio-economic level, n (%)
1 1714 (54.1) 6971 (42.2) 8685 (44.1) <0.001
2 1073 (33.9) 6420 (38.8) 7493 (38.0)
3 309 (9.8) 2654 (89.6) 2963 (15.0)
4 57 (1.8) 383 (2.3) 440 (2.2)
>5 15 (0.5) 109 (0.7) 124 (0.6)
Ethnic group, n (%)
Indigenous 236 (10.3) 1124 (7.8) 1360 (8.1) <0.001
Black 288 (12.6) 1701 (11.8) 1989 (11.9)
White 546 (23.9) 4002 (27.7) 4548 (27.1)
Others (mestizo, gitano/gypsy, etc.). 1212 (53.1) 7646 (52.8) 8858 (52.9)
Smoking status, n (%)
Yes 526 (16.6) 1695 (10.3) 2221 (11.3) <0.001
No 2642 (83.4) 14 840 (89.7) 17 482 (88.7)
Physical activity ‘proxy’, n (%)
Yes 3190 (19.3) 375 (11.8) 3565 (18.1) <0.001
No 13 327 (80.7) 2790 (88.2) 16 117 (81.9)
Mobility disability, n (%)
No 2120 (66.9) 11 810 (71.4) 13 930 (70.7) <0.001
Barely 502 (15.8) 2505 (15.1) 3007 (15.3)
Some problems 275 (8.7) 1138 (6.9) 1413 (7.2)
A lot of problems 249 (7.9) 1008 (6.1) 1257 (6.4)
Cannot walk 400 m, or climb a ﬂight
of stairs without rest.
17 (0.5) 63 (0.4) 92 (0.4)
Body mass index, mean (SD) 22.4 (3.7) 27.9 (4.6) 27.0 (4.9) <0.001
Nutritional status, n (%)
Malnutrition 282 (8.9) 413 (2.5) 650 (3.3) <0.001
Risk of malnutrition 1603 (50.6) 5325 (32.3) 6838 (34.7)
Normal nutritional status 1283 (40.5) 10 782 (65.2) 12 217 (62.0)
Dependency levels, n (%)
Dependency 1 (0.0) 0 (0.0) 1 (0.0) <0.001
Severe 13 (0.4) 6 (0.1) 19 (0.1)
Moderate 250 (7.9) 836 (5.1) 1086 (5.5)
Mild 357 (11.3) 1433 (8.7) 1790 (9.1)
Non-dependency 2547 (80.4) 14 262 (86.2) 16 809 (85.3)
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Figure 2 shows the mediation models used to determine
whether the performance in physical function could mediate
the adverse effect of sarcopenia on dependency. In Figure 2,
the regression a (β = 0.02; P = 0.001) indicated that
sarcopenia leads to lower gait speed, and b (β = 0.25;
P < 0.001) shows a signiﬁcant direct relationship between
higher gait speed and less functional dependence. Also, a di-
rect effect (β = 0.05; P < 0.001) was observed for the ad-
verse outcome of sarcopenia on functional dependence.
Our mediational hypothesis was conﬁrmed because the con-
ﬁdence intervals did not include zero (0.009 to 0.004);
therefore, gait speed has a mediation effect on the relation-
ship between sarcopenia and functional dependence.
Discussion
The major ﬁndings of our analysis were that sarcopenia may
negatively inﬂuence the independence in ADL in older adults,
but this adverse association could be counteracted if physical
function performance does not decline. Therefore, gait speed
may positively inﬂuence the detrimental effect of sarcopenia
for dependency, after adjusting for age, gender, and BMI.
Older adults who present characteristics of sarcopenia but
have a better gait speed than their fewer ﬁt peers will show
better functional dependency in ADL, because the association
between sarcopenia and dependence was mediated for this
physical ﬁtness component. Our results thus contribute to
the current knowledge by providing evidence that presenting
a better proﬁle in gait speed may ameliorate the negative im-
pact of sarcopenia on dependency.
CC is an anthropometric parameter that is closely related to
whole body muscle mass and is known to be associated with
the nutrition status of the elderly population.22 Our ﬁndings
indicate that lower CC, a valid predictor of sarcopenia,18,19
might increase the risk of dependency in older adults. This re-
sult is similar to previous cross-sectional studies in which lower
CC was associated with poor functioning in basic ADL, indicat-
ing the high dependency of these patients and a high necessity
of care.20,32 Our results also suggest that sarcopenia induces a
lower gait speed. Indeed, it is well documented that the dete-
rioration of gait speed related to sarcopenia during aging is
due to quantitative and qualitative changes in muscle struc-
ture and function.1 We also found that the lower the gait
speed, the greater dependency, which is in accord with the lit-
erature on this topic,6,33 in which a lower gait speed is related
to more problems in ADL. Accordingly, physical activity fo-
cused on counteracting the decline in gait speed could prevent
functional dependency. Overall, our ﬁndings are consistent
with previous studies presenting strong evidence on the pre-
ventive role of gait speed on all-cause mortality.24 Conse-
quently, the mediator role of gait speed between sarcopenia
and dependence has robustness.
Our results clearly show the differences between older
adults with sarcopenia and non-sarcopenia in the performance
in gait speed and the level of dependence. As shown in previ-
ous studies, our ﬁndings conﬁrm that sarcopenia results in
lower gait speed18,34 and independence in daily living.6,35 Con-
sequently, the promotion of physical activity in older adults is
key to maintain the muscle mass to prevent the deterioration
of gait speed. In this line, it seems that preventing the
deterioration of gait speed is crucial, because it has been
shown to be the physical function component more related
to sarcopenia, functional independence, vitality, and
frailty22,35–37 and is used as a signiﬁcant predictor of frailty
and all-cause mortality.22,38 Furthermore, recent studies have
Table 2 Associations between sarcopenia and gait speed and depen-
dency in older adults
Outcome variable β P-value 95% CI
Gait speed
Model 1 0.040 <0.001 (0.038 to 0.017)
Model 2 0.021 0.001 (0.033 to 0.009)
Model 3 0.017 0.006 (0.029 to 0.005)
Dependency
Model 1 0.066 <0.001 (0.088 to 0.044)
Model 2 0.017 0.007 (0.055 to 0.009)
Model 3 0.019 0.101 (0.041 to 0.004)
Model 1 = adjusted by sex, age, and body mass index; Model
2 = adjusted by Model 1 + nutritional status; Model 3 = adjusted
by Model 2 + mobility disability.
Figure 2 Gait speed as mediator of the effect of sarcopenia on dependency in activities daily living. BMI, body mass index.
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related a decline in gait speed, sarcopenia, pro-inﬂammatory
biomarkers, and functional dependence,39,40 fostering a vi-
cious cycle that may be broken with physical exercise.9
There are several plausible explanations for our ﬁnding.
First, there was a close relationship between sarcopenia,
physical performance (gait speed), and dependency. Muscle
mass is a metabolic tissue and endocrine organ, and the con-
struction of muscle mass releases several endocrines called
myokines, produced, expressed, and released by muscle ﬁ-
bres under contraction, and exerts both local and pleiotropic
effects.39 In this line, reports of a previous cross-sectional
study show a greater proportion of low muscle density in
older people with a lower CC scores; moreover, an associa-
tion was found between high BMI and increased functional
disability and the presence of comorbidities and coexisting
factors of disability. In addition, reduced muscular strength
is known to be signiﬁcantly and independently associated
with functional impairment, walking speed, mobility tasks,
physical performance, and all-cause mortality in the elderly
population.39,40 Accordingly, gait speed performance, which
is related to muscle mass quality, may be one mechanism
for the mediator role between sarcopenia and dependence.
Our study has several limitations that warrant consider-
ation. First, the cross-sectional design of the study limits the
causality of the ﬁndings and only associations can be drawn,
providing hypotheses that can be veriﬁed in future studies. A
second limitation is the criteria used to establish sarcopenia
and non-sarcopenia groups, since the European Working
Group on Sarcopenia in Older People proposes an algorithm
for sarcopenia case-ﬁnding and not only CC; however, it seems
that CC is a valid and reliable method to diagnose
sarcopenia.18,19 Another limitation that could affect the re-
sults of this study is the level of functional dependence, be-
cause this was assessed through a self-reported
questionnaire.41
To the best of our knowledge, this is the ﬁrst study aimed
at investigating the possible role of gait speed performance in
the relationship between sarcopenia and functional depen-
dence. As previously discussed, there is an adverse effect of
sarcopenia on functional dependence in older adults, and de-
pending on the level of gait speed, this adverse effect could
be aggravated or improved. Thus, gait speed plays a mediator
role between sarcopenia and dependence in ADL.
Conclusions and implications
The relationship between sarcopenia and functional depen-
dence is mediated by gait speed, which can attenuate this
negative impact. Accordingly, promoting physical exercise in
older adults with sarcopenia focused on improving gait speed
should counteract the loss of functional independence associ-
ated with sarcopenia.
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